Improving the diagnosis and stratification of cardiovascular disease
- Heart failure (HF) is a global health problem associated with high morbidity and mortality
- Detection in its early stages and appropriate treatment are key to improving quality of life
- Patients with HF – especially with mild symptoms – are often not diagnosed
- In addition many patients with suspicion of HF are unnecessarily referred to echocardiography
- NT-proBNP is an innovative marker to improve clinical decisions, delivering accurate data to help ‘rule-out’, ‘rule-in’, risk-stratify or monitor patients
- NT-proBNP - the inactive hormone - is more stable under a variety of conditions, provides a longer in vivo and in vitro half-life and offers more flexible test tube selection compared to BNP
|Assay Time||9 min as STAT assay|
|Sample Material||standard serum and heparin/EDTA plasma|
|Sample Volume||50 μL|
|Measuring Range||5 - 35,000 ng/L|
|Intermediate precision||2.9 - 6.1 %|
|Sample stability||3 days at room temperature and even longer on 4°C|
Improving patient care with early and accurate diagnosis
Simplified testing process and improved efficiency
- Inherent stability of NT-proBNP allows cardiac profile testing from one tube
- Between all cobas immunoassay analyzers and POC devices
- In cases of dyspnoe; differentiation between cardiac or pulmonary causes
Early diagnosis of heart failure
- Even in early stages without symptoms
- NT-proBNP concentration correlates with the severity of disease
- High predictive value in cardiology-risk patients
- Helps with evaluation of the clinical situation and optimization of therapy
Heart Failure: Acute Setting Rule In, Rule Out
NT-proBNP concentration aides in the differential diagnosis of dyspnic patients and is strongly predictive of short-term mortality.
Januzzi, J.L., et al. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95, 948-954.
Januzzi, J.L., van Kimmenade, R., Lainchbury, J. (2006). N-terminal Pro-BNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An International Collaboration of NT-proBNP Study. Eur Heart J 27, 330-337.
Heart Failure Monitoring and Guidance:
Newer studies have proven NT-proBNP can improve patient outcomes and decrease cost while maintaining safety.
Use of biomarkers to guide outpatient therapy of heart failure:
Deberadinis, B., Januzzi, J.L. Jr. (2012) Curr Opin Cardiol Aug 30.
Felker, M. (2009). N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. Am Heart J, 158, 422.
Berger, R., Moertl, D., Peter, S., Ahmadi, R., Huelsmann, M., Yamuti, S., Wagner, B., Pacher, R. (2010). N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol, 55(7), 645–653